<DOC>
	<DOCNO>NCT00150215</DOCNO>
	<brief_summary>The purpose study : - To determine safety , tolerability pharmacokinetics single dose PF-00184562 ; - To explore exposure-response relationship neuropsychometric tolerability measure PF-00184562 compare olanzapine .</brief_summary>
	<brief_title>A First In Human Study Of PF-00184562 In Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Healthy male female subject nonchildbearing potential Subjects evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , pancreatic , psychiatric , neurologic , active infection , immunological , allergic disease ( include drug allergy seasonal allergy time dose ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2006</verification_date>
</DOC>